MX2009013070A - Compuesto novedoso. - Google Patents
Compuesto novedoso.Info
- Publication number
- MX2009013070A MX2009013070A MX2009013070A MX2009013070A MX2009013070A MX 2009013070 A MX2009013070 A MX 2009013070A MX 2009013070 A MX2009013070 A MX 2009013070A MX 2009013070 A MX2009013070 A MX 2009013070A MX 2009013070 A MX2009013070 A MX 2009013070A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- formula
- medicament
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención presente revela una novela tiroides como compuestos de fórmula (I), en donde R1, R2, R3, R4 y Z son tal como se define en la especificación, el método para su preparación, composición que incluyan compuestos y el uso de tales compuestos y composición como medicamentos. Además, compuestos de fórmula (I) tiene afinidad de enlace significativamente bajo los receptores de tiroides y, por lo tanto, considerablemente vacíos de efectos tirotóxica. La invención también se relaciona con el uso del compuesto de fórmula (I) para la preparación de un medicamento para el tratamiento de diversas condiciones de la enfermedad, como la obesidad, dislipidemia, síndrome metabólico y comorbilidades asociadas con el síndrome metabólico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN857KO2007 | 2007-06-06 | ||
| PCT/IN2008/000345 WO2008149379A2 (en) | 2007-06-06 | 2008-06-02 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009013070A true MX2009013070A (es) | 2010-01-29 |
Family
ID=39828965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013070A MX2009013070A (es) | 2007-06-06 | 2008-06-02 | Compuesto novedoso. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8143424B2 (es) |
| EP (1) | EP2061766B1 (es) |
| JP (1) | JP5243537B2 (es) |
| KR (1) | KR101152965B1 (es) |
| CN (1) | CN101772487B (es) |
| AR (1) | AR066155A1 (es) |
| AT (1) | ATE478053T1 (es) |
| AU (1) | AU2008259314B2 (es) |
| CA (1) | CA2698704C (es) |
| CY (1) | CY1110925T1 (es) |
| DE (1) | DE602008002205D1 (es) |
| DK (1) | DK2061766T3 (es) |
| EA (1) | EA019084B1 (es) |
| ES (1) | ES2351274T3 (es) |
| HR (1) | HRP20100611T1 (es) |
| IL (1) | IL202515A (es) |
| MX (1) | MX2009013070A (es) |
| NZ (1) | NZ582273A (es) |
| PL (1) | PL2061766T3 (es) |
| PT (1) | PT2061766E (es) |
| RS (1) | RS51501B (es) |
| SI (1) | SI2061766T1 (es) |
| TW (1) | TWI360541B (es) |
| UA (1) | UA98962C2 (es) |
| WO (1) | WO2008149379A2 (es) |
| ZA (1) | ZA200908760B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9724381B2 (en) * | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| BR112012025343A2 (pt) * | 2010-04-15 | 2016-06-28 | Merck Patent Gmbh | processo para a preparação de hidroquinonas |
| EP2566333A4 (en) * | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS |
| EP4023641B1 (en) | 2012-09-17 | 2024-05-01 | Madrigal Pharmaceuticals, Inc. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
| CN110372550B (zh) * | 2013-09-09 | 2021-08-24 | 佩洛通治疗公司 | 芳基醚及其用途 |
| EP3083639B1 (en) | 2013-12-16 | 2019-05-29 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
| CN103992225B (zh) * | 2014-03-26 | 2016-01-13 | 安徽师范大学 | 一种水杨醛衍生物及其制备方法 |
| WO2016025129A1 (en) | 2014-08-14 | 2016-02-18 | Alhamadsheh Mamoun M | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| ES2968785T3 (es) * | 2014-10-31 | 2024-05-14 | Hoffmann La Roche | Nuevos compuestos de piridiniloxi- y feniloxipirazolilo |
| US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| WO2016144826A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| TW201718510A (zh) | 2015-11-16 | 2017-06-01 | 隆薩有限公司 | 製備1-甲基-3-(三氟甲基)-1h-吡唑-5-醇的方法 |
| RU2621163C1 (ru) * | 2016-02-16 | 2017-05-31 | государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) | Антифибролитическое средство |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| NZ797281A (en) | 2017-02-17 | 2025-10-31 | Eidos Therapeutics Inc | Processes for preparing ag-10, its intermediates, and salts thereof |
| MY208459A (en) | 2018-03-23 | 2025-05-10 | Eidos Therapeutics Inc | Methods of treating ttr amyloidosis using ag10 |
| FI3836920T3 (fi) | 2018-08-17 | 2025-12-22 | Eidos Therapeutics Inc | AG10-formulaatioita |
| US11560357B2 (en) * | 2018-09-22 | 2023-01-24 | Torrent Pharmaceuticals Limited | Methods of producing pyrazole compounds |
| KR102396602B1 (ko) * | 2019-02-28 | 2022-05-11 | 주식회사 마더스제약 | 피라졸 아마이드 유도체 화합물 및 이의 용도 |
| WO2023047203A1 (en) | 2021-09-25 | 2023-03-30 | Torrent Pharmaceuticals Ltd | Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent |
| CN116063296B (zh) * | 2021-11-02 | 2025-08-19 | 凯思凯迪（上海）医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| JP2025507543A (ja) * | 2022-02-23 | 2025-03-21 | バイオヘイブン・セラピューティクス・リミテッド | Ｋｖ７チャネル活性化剤としてのピラゾリル化合物 |
| EP4482487A1 (en) * | 2022-02-23 | 2025-01-01 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
| IL314554A (en) * | 2022-02-23 | 2024-09-01 | Biohaven Therapeutics Ltd | Pyrazolyl compounds as kv7 channel activators |
| CN116836158A (zh) * | 2022-03-23 | 2023-10-03 | 凯思凯迪（上海）医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| CN114920635B (zh) * | 2022-04-29 | 2023-05-12 | 郑州原理医药研究院有限公司 | 4-羟基-1-茚酮的制备方法 |
| AR129535A1 (es) | 2022-06-21 | 2024-09-04 | Syngenta Crop Protection Ag | Derivados de carboxamida heterocíclicos bicíclicos microbiocidas |
| WO2024089191A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Microbiocidal heterobicyclic dihydrooxadiazine derivatives |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7598596A (en) | 1995-11-01 | 1997-05-22 | Allergan, Inc. | Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity |
| ES2208812T3 (es) | 1997-02-25 | 2004-06-16 | Akzo Nobel N.V. | Derivados de azetidina y de pirrolidina. |
| US6281243B1 (en) * | 1998-02-26 | 2001-08-28 | Akzo Nobel N.V. | Derivatives of azetidine and pyrrolidine |
| US6240678B1 (en) | 1998-07-09 | 2001-06-05 | Karl Heinz Spether | Capping head with torque adjustment |
| OA11839A (en) * | 1999-03-01 | 2005-08-23 | Pfizer Prod Inc | Oxamic acids and derivatives as thyroid receptor ligands. |
| WO2000072811A1 (en) | 1999-06-01 | 2000-12-07 | The University Of Texas Southwestern Medical Center | Method of treating hair loss |
| EP1127882A1 (en) * | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
| US6620830B2 (en) * | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
| CA2457575C (en) * | 2001-08-17 | 2010-12-21 | Sankyo Agro Company, Limited | 3-phenoxy-4-pyridazinol derivatives and herbicidal composition containing the same |
| US7230031B2 (en) * | 2002-01-30 | 2007-06-12 | Kissei Pharmaceutical Co., Ltd. | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| WO2003094845A2 (en) * | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| US7230025B2 (en) * | 2002-09-26 | 2007-06-12 | Pfizer, Inc. | Pyrazole derivatives |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| RU2007148927A (ru) | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| GB0513692D0 (en) * | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| NZ565190A (en) * | 2005-07-21 | 2010-02-26 | Hoffmann La Roche | Pyridazinone derivatives as thyroid hormone receptor agonists |
| WO2007027842A1 (en) | 2005-08-31 | 2007-03-08 | Bayer Healthcare Llc | Anilinopyrazole derivatives useful for the treatment of diabetes |
-
2008
- 2008-06-02 RS RSP-2010/0491A patent/RS51501B/sr unknown
- 2008-06-02 CN CN200880102100.8A patent/CN101772487B/zh not_active Expired - Fee Related
- 2008-06-02 AU AU2008259314A patent/AU2008259314B2/en not_active Ceased
- 2008-06-02 UA UAA200913974A patent/UA98962C2/ru unknown
- 2008-06-02 HR HR20100611T patent/HRP20100611T1/hr unknown
- 2008-06-02 PL PL08772567T patent/PL2061766T3/pl unknown
- 2008-06-02 ES ES08772567T patent/ES2351274T3/es active Active
- 2008-06-02 NZ NZ582273A patent/NZ582273A/en not_active IP Right Cessation
- 2008-06-02 AT AT08772567T patent/ATE478053T1/de active
- 2008-06-02 PT PT08772567T patent/PT2061766E/pt unknown
- 2008-06-02 EA EA200901651A patent/EA019084B1/ru not_active IP Right Cessation
- 2008-06-02 WO PCT/IN2008/000345 patent/WO2008149379A2/en not_active Ceased
- 2008-06-02 DE DE602008002205T patent/DE602008002205D1/de active Active
- 2008-06-02 SI SI200830091T patent/SI2061766T1/sl unknown
- 2008-06-02 DK DK08772567.7T patent/DK2061766T3/da active
- 2008-06-02 US US12/224,168 patent/US8143424B2/en not_active Expired - Fee Related
- 2008-06-02 EP EP08772567A patent/EP2061766B1/en active Active
- 2008-06-02 CA CA2698704A patent/CA2698704C/en active Active
- 2008-06-02 MX MX2009013070A patent/MX2009013070A/es active IP Right Grant
- 2008-06-02 KR KR1020107000236A patent/KR101152965B1/ko not_active Expired - Fee Related
- 2008-06-02 JP JP2010510961A patent/JP5243537B2/ja not_active Expired - Fee Related
- 2008-06-06 AR ARP080102438A patent/AR066155A1/es active IP Right Grant
- 2008-06-06 TW TW097121081A patent/TWI360541B/zh not_active IP Right Cessation
-
2009
- 2009-12-03 IL IL202515A patent/IL202515A/en active IP Right Grant
- 2009-12-09 ZA ZA200908760A patent/ZA200908760B/xx unknown
-
2010
- 2010-11-18 CY CY20101101041T patent/CY1110925T1/el unknown
-
2012
- 2012-01-10 US US13/346,968 patent/US8378118B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013070A (es) | Compuesto novedoso. | |
| DE602007004324D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| DE602007007473D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| MY148128A (en) | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| MX2009011205A (es) | Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide. | |
| MY148657A (en) | Trpv1 antagonists and uses thereof | |
| WO2010028338A3 (en) | Novel compounds as cannabinoid receptor ligands | |
| CY1112398T1 (el) | Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1 | |
| WO2007127763A3 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| MX2009005462A (es) | Analogos de 7,8-saturados-4,5-epoxi-morfinano. | |
| TNSN08432A1 (en) | Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| TW200716584A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| MX2009012374A (es) | Compuestos novedosos como ligandos del receptor de canabinoides. | |
| EP4545137A3 (en) | A stable iron oligosaccharide compound | |
| ZA201003221B (en) | Tea composition and process for the manufacture thereof | |
| WO2010062927A3 (en) | Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers | |
| PT2280706E (pt) | Composições compreendendo derivados de benzeno que activam lipase de lipoproteína | |
| WO2008147812A3 (en) | 4' substituted compounds having 5-ht6 receptor affinity | |
| EA201000926A1 (ru) | Пиперазины в качестве агентов против ожирения | |
| MX2009003617A (es) | Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones (pet). | |
| WO2007095021A3 (en) | Novel compounds | |
| MX2010006215A (es) | Derivados de piperazina y su uso como moduladores del receptor de leptina. | |
| MX2010006216A (es) | Nuevos compuestos iii. | |
| IN2012DN01245A (es) | ||
| TW200628167A (en) | Composition for preventing and/or treating metabolic syndrome and insulin resistance syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |